blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2931750

EP2931750 - ANTIBODIES AGAINST IL-1 BETA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.08.2022
Database last updated on 28.06.2024
FormerThe patent has been granted
Status updated on  27.08.2021
FormerGrant of patent is intended
Status updated on  27.04.2021
FormerExamination is in progress
Status updated on  26.02.2021
FormerGrant of patent is intended
Status updated on  26.10.2020
FormerExamination is in progress
Status updated on  07.11.2016
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Cell Medica Inc.
6200 Savoy Dr., 1200
Houston, TX 77036 / US
[2021/44]
Former [2015/43]For all designated states
Delenex Therapeutics AG
Wagistrasse 27
8952 Schlieren / CH
Inventor(s)01 / HONEGGER, Annemarie
Murwiesenstrasse 32
CH-8057 Zürich / CH
02 / KRETZSCHMAR, Titus
Sonnhaldenstrasse 63b
6331 Hühnenberg / CH
03 / SCHMITT, Simone
Zürcherstrasse 80
8953 Dietikon / CH
04 / SHAMSHIEV, Abdijapar
Buchzelgstrasse 64
CH-8053 Zürich / CH
05 / GRABULOVSKI, Stefanie
Riedhofstrasse 57
CH-8049 Zürich / CH
 [2015/43]
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstraße 4
80802 München / DE
[2021/39]
Former [2015/43]Grimm, Siegfried, et al
E. Blum & Co. AG
Vorderberg 11
8044 Zürich / CH
Application number, filing date13805897.917.12.2013
[2015/43]
WO2013EP76831
Priority number, dateUS201261738223P17.12.2012         Original published format: US 201261738223 P
EP2013000074614.02.2013         Original published format: EP 13000746
[2015/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014095808
Date:26.06.2014
Language:EN
[2014/26]
Type: A1 Application with search report 
No.:EP2931750
Date:21.10.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 26.06.2014 takes the place of the publication of the European patent application.
[2015/43]
Type: B1 Patent specification 
No.:EP2931750
Date:29.09.2021
Language:EN
[2021/39]
Type: B8 Corrected title page of specification 
No.:EP2931750
Date:03.11.2021
[2021/44]
Search report(s)International search report - published on:EP26.06.2014
ClassificationIPC:C07K16/24
[2015/43]
CPC:
C07K16/245 (EP,US); A61P29/00 (EP); A61P3/10 (EP);
G01N33/6869 (US); C07K2317/24 (EP,US); C07K2317/33 (EP,US);
C07K2317/35 (US); C07K2317/41 (US); C07K2317/54 (US);
C07K2317/55 (US); C07K2317/56 (EP,US); C07K2317/565 (EP,US);
C07K2317/569 (US); C07K2317/622 (US); C07K2317/76 (EP,US);
C07K2317/94 (EP,US); G01N2333/545 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/43]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ANTIKÖRPER GEGEN IL-1 BETA[2015/43]
English:ANTIBODIES AGAINST IL-1 BETA[2015/43]
French:ANTICORPS DIRIGÉS CONTRE IL-1 BÉTA[2020/35]
Former [2015/43]ANTICORPS CONTRE IL-1 BÊTA
Entry into regional phase10.07.2015National basic fee paid 
10.07.2015Designation fee(s) paid 
10.07.2015Examination fee paid 
Examination procedure10.07.2015Examination requested  [2015/43]
06.02.2016Amendment by applicant (claims and/or description)
27.10.2016Despatch of a communication from the examining division (Time limit: M06)
21.04.2017Reply to a communication from the examining division
06.11.2017Despatch of a communication from the examining division (Time limit: M07)
18.06.2018Reply to a communication from the examining division
05.04.2019Despatch of a communication from the examining division (Time limit: M06)
03.10.2019Reply to a communication from the examining division
19.06.2020Despatch of a communication from the examining division (Time limit: M01)
22.07.2020Reply to a communication from the examining division
27.10.2020Communication of intention to grant the patent
25.02.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
28.04.2021Communication of intention to grant the patent
20.08.2021Fee for grant paid
20.08.2021Fee for publishing/printing paid
20.08.2021Receipt of the translation of the claim(s)
Divisional application(s)EP21199413.2  / EP4001307
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  27.10.2016
Opposition(s)30.06.2022No opposition filed within time limit [2022/36]
Fees paidRenewal fee
31.10.2015Renewal fee patent year 03
03.11.2016Renewal fee patent year 04
26.10.2017Renewal fee patent year 05
12.12.2018Renewal fee patent year 06
13.12.2019Renewal fee patent year 07
14.12.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.12.2013
AL29.09.2021
AT29.09.2021
CY29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
MK29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SI29.09.2021
SK29.09.2021
SM29.09.2021
IE17.12.2021
LU17.12.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
CH31.12.2021
LI31.12.2021
IS29.01.2022
PT31.01.2022
[2024/22]
Former [2023/33]HU17.12.2013
AL29.09.2021
AT29.09.2021
CY29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SI29.09.2021
SK29.09.2021
SM29.09.2021
IE17.12.2021
LU17.12.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
CH31.12.2021
LI31.12.2021
IS29.01.2022
PT31.01.2022
Former [2023/30]HU17.12.2013
AL29.09.2021
AT29.09.2021
CY29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SI29.09.2021
SK29.09.2021
IE17.12.2021
LU17.12.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
CH31.12.2021
LI31.12.2021
IS29.01.2022
PT31.01.2022
Former [2023/29]HU17.12.2013
AL29.09.2021
AT29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SI29.09.2021
SK29.09.2021
IE17.12.2021
LU17.12.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
CH31.12.2021
LI31.12.2021
IS29.01.2022
PT31.01.2022
Former [2023/03]AL29.09.2021
AT29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SI29.09.2021
SK29.09.2021
IE17.12.2021
LU17.12.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
CH31.12.2021
LI31.12.2021
IS29.01.2022
PT31.01.2022
Former [2023/01]AL29.09.2021
AT29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SI29.09.2021
SK29.09.2021
IE17.12.2021
LU17.12.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2022/48]AL29.09.2021
AT29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SK29.09.2021
IE17.12.2021
LU17.12.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2022/46]AL29.09.2021
AT29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SK29.09.2021
LU17.12.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2022/35]AL29.09.2021
AT29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SK29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2022/33]AL29.09.2021
AT29.09.2021
EE29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SK29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2022/29]AL29.09.2021
AT29.09.2021
EE29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SK29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2022/24]AT29.09.2021
EE29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SK29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2022/23]AT29.09.2021
EE29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
PL29.09.2021
RS29.09.2021
SK29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
PT31.01.2022
Former [2022/21]AT29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
RS29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
Former [2022/10]FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
RS29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
Former [2022/09]FI29.09.2021
LT29.09.2021
RS29.09.2021
BG29.12.2021
NO29.12.2021
Former [2022/08]FI29.09.2021
LT29.09.2021
BG29.12.2021
NO29.12.2021
Former [2022/07]LT29.09.2021
NO29.12.2021
Cited inInternational search[A]US2003026806  (WITTE ALISON [US], et al) [A] 1-38* the whole document *;
 [X]WO2007002261  (XOMA TECHNOLOGY LTD [US], et al) [X] 1-38 * Abs 1-9;; sequences 11, 15 *;
 [X]WO2011140522  (XOMA TECHNOLOGY LTD [US], et al) [X] 1-38 * Abs 5 and 7;; sequences 5,6 *
ExaminationUS2003026806
 WO2004067568
 WO2007002261
 WO2011140522
    - ALTEN RIEKE ET AL, "The human anti-IL-1Î monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, (20080605), vol. 10, no. 3, ISSN 1478-6354, page R67, XP021041234
    - Rieke Alten ET AL, "Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study July 2011) Background", BMC Musculoskeletal Disorders, (20110101), page 153, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152943/pdf/1471-2474-12-153.pdf, (20171031), XP055420326
    - Jianying Qi ET AL, "A bispecific antibody against IL-1β and IL-17A is beneficial for experimental rheumatoid arthritis", International Immunopharmacology, (20121201), vol. 14, no. 4, doi:10.1016/j.intimp.2012.10.005, ISSN 1567-5769, pages 770 - 778, XP055140680

DOI:   http://dx.doi.org/10.1016/j.intimp.2012.10.005
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.